These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30133757)

  • 1. Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
    van Duijn PW; Marques RB; Ziel-van der Made ACJ; van Zoggel HJAA; Aghai A; Berrevoets C; Debets R; Jenster G; Trapman J; van Weerden WM
    Prostate; 2018 Sep; 78(13):1013-1023. PubMed ID: 30133757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer.
    Adissu HA; McKerlie C; Di Grappa M; Waterhouse P; Xu Q; Fang H; Khokha R; Wood GA
    Prostate; 2015 Dec; 75(16):1831-43. PubMed ID: 26332574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
    Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
    PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
    Ma X; Ziel-van der Made AC; Autar B; van der Korput HA; Vermeij M; van Duijn P; Cleutjens KB; de Krijger R; Krimpenfort P; Berns A; van der Kwast TH; Trapman J
    Cancer Res; 2005 Jul; 65(13):5730-9. PubMed ID: 15994948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice.
    Korsten H; Ziel-van der Made AC; van Weerden WM; van der Kwast T; Trapman J; Van Duijn PW
    PLoS One; 2016; 11(1):e0147500. PubMed ID: 26807730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
    Tan M; Xu J; Siddiqui J; Feng F; Sun Y
    Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic and transcriptomic profiling of Pten gene-knockout mouse model of prostate cancer.
    Zhang J; Kim S; Li L; Kemp CJ; Jiang C; Lü J
    Prostate; 2020 May; 80(7):588-605. PubMed ID: 32162714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model.
    Korsten H; Ziel-van der Made A; Ma X; van der Kwast T; Trapman J
    PLoS One; 2009 May; 4(5):e5662. PubMed ID: 19461893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma.
    Ratnacaram CK; Teletin M; Jiang M; Meng X; Chambon P; Metzger D
    Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2521-6. PubMed ID: 18268330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
    Yamamoto Y; De Velasco MA; Kura Y; Nozawa M; Hatanaka Y; Oki T; Ozeki T; Shimizu N; Minami T; Yoshimura K; Yoshikawa K; Nishio K; Uemura H
    J Transl Med; 2015 May; 13():150. PubMed ID: 25953027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal.
    Salah M; Nishimoto Y; Kohno S; Kondoh A; Kitajima S; Muranaka H; Nishiuchi T; Ibrahim A; Yoshida A; Takahashi C
    Mol Carcinog; 2016 Dec; 55(12):1974-1989. PubMed ID: 26621780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
    Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
    Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aqueous metabolome of tissue-specific conditional Pten-knockout mouse prostate cancer and TRAMP neuroendocrine carcinoma.
    Kim S; Li L; Zhang J; Jiang C; Lü J
    Prostate; 2022 Jan; 82(1):154-166. PubMed ID: 34662447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer.
    Allott EH; Masko EM; Freedland AR; Macias E; Pelton K; Solomon KR; Mostaghel EA; Thomas GV; Pizzo SV; Freeman MR; Freedland SJ
    Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):196-203. PubMed ID: 29795142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
    Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
    Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model.
    Kwon OJ; Zhang L; Wang J; Su Q; Feng Q; Zhang XH; Mani SA; Paulter R; Creighton CJ; Ittmann MM; Xin L
    J Clin Invest; 2016 Jul; 126(7):2626-41. PubMed ID: 27294523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel syngeneic mouse mammary carcinoma cell lines from aggressive ErbB2/Neu-overexpressing/PTEN-deficient tumors.
    Wang Q; Ding H; Wang H; Li P; Liu B; Zhang K
    Oncol Rep; 2015 Jan; 33(1):179-84. PubMed ID: 25354531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased T-cell Infiltration Elicited by
    Loveridge CJ; Mui EJ; Patel R; Tan EH; Ahmad I; Welsh M; Galbraith J; Hedley A; Nixon C; Blyth K; Sansom O; Leung HY
    Cancer Res; 2017 Jun; 77(12):3158-3168. PubMed ID: 28515147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
    De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
    Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.